Scientists at King’s College London have found that people who are likely to get rheumatoid arthritis (RA) can keep the disease away for many years by starting a special medicine early.
The medicine is called abatacept. In the study, participants took it for just one year. After that, they waited longer before RA showed up compared with those who took a harmless pill (placebo). In some cases, the disease was delayed by up to four extra years.
The research was published in The Lancet Rheumatology. It builds on an earlier trial that followed 213 volunteers from the UK and the Netherlands for two years. The new analysis watched the same people for four to eight years, making it one of the longest follow‑up studies for people at risk of RA.
Why Early Treatment Matters
Rheumatoid arthritis is an autoimmune disease. That means the body’s own immune system attacks the joints by mistake. The result is pain, swelling, tiredness and, over time, damage that can’t be fixed.
About half a million people in the UK live with RA. Many who are at risk feel sick or lose their jobs before doctors can officially diagnose them. Right now, doctors have medicines that help people who already have RA, but there is no approved drug that stops the disease before it starts.
How the Study Was Done
Researchers gave a group of high‑risk volunteers abatacept for 12 months. Another group received a placebo. They then watched both groups for several more years.
People who took abatacept got RA later than the placebo group. The delay was biggest in those who had the highest chance of developing the disease, based on blood tests that look for certain auto‑antibodies.
What Participants Felt
During the treatment year, the abatacept group reported less joint pain and felt less tired. Their overall mood was also better. After the drug was stopped, symptoms in both groups became similar, suggesting that continued immune‑system support might be needed for lasting relief.
Safety Checks
The drug appeared safe. Serious side‑effects happened at about the same rate in the abatacept and placebo groups. No new safety problems were found.
What This Means for the Future
These findings give hope that treating auto‑immune conditions early can change how the disease runs. They show that targeted therapies like abatacept can push back the start of rheumatoid arthritis in people who are most likely to get it. The study also encourages more research into ways to prevent, not just treat, autoimmune diseases.